Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Remo PanaccioneSilvio DaneseWen ZhouJustin KlaffDapo IloXuan YaoGweneth LevyPeter D R HigginsEdward V LoftusSu ChenYuri Sanchez GonzalezCarolyn LeonardXavier HébuterneJames O LindsayQian CaoHiroshi NakaseJean Frederic ColombelSéverine VermeirePublished in: Alimentary pharmacology & therapeutics (2023)
NCT02819635; NCT03653026.